Atopic Dermatitis | Emerging Therapies | Eucrisa | USis a three-wave series that tracks the introduction of Pfizer’s Eucrisa for the treatment of AD. The series is based on primary research data collected at 1, 6, and 12 months post-commercial launch from surveys of U.S. dermatologists. Along with awareness of, sources of familiarity with, and perceptions related to Eucrisa, the research assesses trial, adoption, and usage, including anticipated future trends, of Eucrisa. We also explore Pfizer’s promotional efforts, prescriber and nonprescriber profiles, and benchmarking against other previously launched immune agents.

What you will learn in this content:

  • What is U.S. dermatologists' awareness of and familiarity with Eucrisa, and what are their perceptions of this product?
  • Among prescribers, for which patients are they prescribing Eucrisa, what are the reasons for prescribing, and how satisfied are they with Eucrisa?
  • What are the promotional messages and activities that Pfizer is employing in support of the Eucrisa launch?
  • How do prescribers and nonprescribers compare across key metrics?
  • How is the trial and adoption of Eucrisa tracking compared with other recent product launches in the AD market?

Methodology: ~75-100 U.S. dermatologists complete a 30-minute online quantitative survey with several open-ended questions for qualitative feedback.

Key drugs: Eucrisa

Key companies: Pfizer

Related reports: Atopic Dermatitis Disease Landscape and Forecast, Atopic Dermatitis Unmet Need, Access and Reimbursement – Atopic Dermatitis (US), Access and Reimbursement – Atopic Dermatitis (EU)

Table of contents

  • Atopic Dermatitis/Atopic Eczema - Emerging Therapies - Eucrisa Launch Tracking Wave 1 (US)
    • Key Findings
      • Benchmarking Eucrisa's Launch Success vs. Other Launched Drugs
        • Key Findings
        • Benchmarking Table Across Brands
      • Prescriber and Nonprescriber Profiles
        • Differences Between Eucrisa Prescribers and Nonprescribers
        • Differences Between Eucrisa Prescriber and Nonprescriber Profiles
      • Eucrisa Awareness and Perceptions
        • Unaided and Aided Awareness of Eucrisa
          • Awareness of Eucrisa
          • Awareness of Eucrisa's Approval for AD
          • Awareness of the Administration of Eucrisa
          • Estimated Cost of Eucrisa
          • Unaided Awareness of Drugs Used for the Treatment of Atopic Dermatitis
        • Familiarity with Eucrisa
          • Sources of Familiarity with Eucrisa
            • Initial Reaction to and Interest in Eucrisa
              • Initial Reaction to Eucrisa After Viewing Product Profile
              • Level of Interest in Eucrisa
            • Impressions of Eucrisa
              • Existence of Eucrisa Attributes About Which Dermatologists Were Unaware
              • Perceived Uniqueness of Eucrisa
              • Perceived Value of Eucrisa Attributes
              • Risk-Benefit Ratio of Eucrisa
              • Aspects of Eucrisa Profile About Which Dermatologists Were Unaware
              • Unaided Advantages of Eucrisa
              • Unaided Disadvantages of Eucrisa
            • Prescriber and Nonprescriber Profiles
              • Eucrisa Prescriber and Nonprescriber Profiles
          • Eucrisa Trial and Use
            • Willingness to Prescribe Eucrisa
              • Willingness to Prescribe Eucrisa to Patients
              • Impact of Attributes Willingness to Prescribe Eucrisa
              • Mean Impact of Attributes on Willingness to Prescribe Eucrisa
            • Number of Patients Currently Receiving Eucrisa
              • Agents Currently Prescribed to AD Patients
              • Eucrisa Patient Volume
              • Timing of Eucrisa Prescription
              • Eucrisa Patients by Disease Severity
              • Eucrisa Discontinuation Rate
              • Reasons for Discontinuing Eucrisa
              • Agents Switched to by Discontinued Eucrisa Patients
              • Length of Time on Eucrisa Before Discontinuation
              • Origination of Patients Treated with Eucrisa
              • Replaced Therapies for Patients Switched to Eucrisa
              • Reasons for Switching to Eucrisa from Previous Therapy
              • Background Therapies for Patients Prescribed Adjunct Eucrisa
              • Reasons for Prescribing Eucrisa
            • Reasons for Not Yet Prescribing Eucrisa
              • Anticipated Eucrisa Use
                • Number of Patient Inquiries for Eucrisa
                • Result of Specific Patient Requests for Eucrisa
                • Nonprescriber Timeline for Eucrisa Trial
                • Candidates for Eucrisa by AD Patient Population
                • Candidates for Eucrisa by Treatment History
                • Therapies Eucrisa Is Likely to Replace
                • Reasons for Not Prescribing Eucrisa More
                • Percentage of Patients Expected to Receive Prescription Drug Treatment for AD in Next Six Months
                • Agents That Dermatologists Expect to Prescribe to Patients in the Next Six Months
              • Eucrisa Performance on Key Attributes
                • Overall Satisfaction with Eucrisa
                • Ease of Eucrisa's Managed Care Approval Process
                • Requirements for Eucrisa's Managed Care Approval
                • Eucrisa Performance on Key Attributes
                • Mean Eucrisa Performance on Key Attributes
                • Total Eucrisa Performance on Key Attributes
                • Mean Total Eucrisa Performance on Key Attributes
            • Effectiveness of Face-to-Face Detailing for Eucrisa
              • Eucrisa Sales Representative Frequency and Reach
                • Duration Since Last Contact with Eucrisa Sales Representative
                • Frequency of Visits by Eucrisa Representative
              • Satisfaction with Eucrisa Sales Representative
                • Eucrisa Sales Representative Performance
                • Mean Eucrisa Sales Representative Performance
              • Eucrisa Message Recall
                • Treatments Positioned Against Eucrisa by Representatives
                • Message Recall During Recent Detail
            • Appendix
              • Primary Market Research
                • Age Distribution of AD Patients Under Management
                • Diagnosis Criteria for AD Severity

          Author(s): Emily Schriner, M.P.H.

          Emily Schriner, M.P.H., is a business insights analyst on the Immune and Inflammatory Disorders team at DRG, part of Clarivate. She has authored several content pieces for immune market research reports and keeps the team up-to-date on the immune markets through research on patent life, pricing, and pipeline information. Ms. Schriner earned her master's degree in public health in nutrition at West Chester University of Pennsylvania. She completed an internship at Nemours Health Network in Wilmington, Delaware.

          Related Reports

          Atopic Dermatitis/Atopic Eczema - Landscape & Forecast - Disease Landscape & Forecast

          Atopic dermatitis (AD) is a chronic inflammatory skin disease marked by pruritus and eczema; the main goals of treatment are to protect the skin barrier, redu...

          View Details